Allogene Therapeutics (ALLO) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Valneva (VALN) over the past year, gaining 5.9% versus a loss of 44.9%. Over five years, VALN leads with a -79.1% price change compared with -91.3% for ALLO. Valneva is the larger company by market cap ($556.6 million vs $494.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | VALN |
|---|---|---|
| Share price | $1.43 | $5.87 |
| Market cap | $494.05M | $556.61M |
| 1-day change | -2.05% | +0.17% |
| YTD return | +4.38% | -33.45% |
| 1-year return | +5.93% | -44.88% |
| 5-year return | -91.32% | -79.07% |
| Forward P/E | — | 4.93 |
| EPS (TTM) | $-0.66 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $12.18 |
| 52-week low | $1.04 | $4.75 |
| Distance from 52-week high | -67.94% | -51.81% |
| Analyst consensus | none | buy |
| Avg. price target upside | +529.37% | +108.69% |
| Average volume | 5.65M | 78.15K |
| Shares outstanding | 345.49M | 94.82M |
| Employees | 150 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed VALN by 50.8 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
ALLO vs VALN FAQ
Which is bigger, Allogene Therapeutics or Valneva?
Valneva (VALN) is larger, with a market capitalization of $556.61M compared with $494.05M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or VALN?
ALLO returned +5.93% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.